soul trial oral semaglutide cardiovascular outcomes results 2024 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SOUL: Oral Semaglutide Bests Usual

10.1158/1078-0432.CCR-19-3975 250 YangJ.ZhouY.XieS.WangJ.LiZ.ChenL.et al (2021)

[DOI] [PubMed] [Google Scholar] Karthikeyan K, Bai BR, Devaraj SN

Key Benefits & Added Enhancements: GLP-1 Activation & Appetite Regulation:Berberine, EGCG (Green Tea 50%), CLA, Tesofensine, Chromium, and Cinnamon Extract stimulate GLP-1 release, regulate appetite, and improve glycemic control, supporting fat metabolism, satiety, and insulin efficiency

If you have questions about Ozempic interactions or medication management, speaking with a licensed provider is always the right next step

(April 8, 2025) As glucagon-like peptide 1 (GLP-1) prescription medications commonly used for diabetes management and weight loss continue to increase in popularity, some findings reveal side effects that could affect oral health

All other data supporting the findings of this study are available from the corresponding authors on reasonable request